# Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

> **NCT07631637** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 150 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatohepatitis (MASH)

## Interventions

- **DRUG:** ALN-CIDEB
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07631637
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2029-02-06
- **Final completion:** 2029-02-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631637, "Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07631637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*